
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is looking to be a promising long-term investment with its focus on developing therapies for neurodegenerative and inflammatory diseases. With a strong pipeline, the company is expected to achieve positive clinical data from ALSTARS and its upcoming phase II study of COYA 302 in frontotemporal dementia. Although risks to financial performance and valuation exist, the company's biomarker strategy and combination therapies show potential for success in the market.
Bears say
Coya Therapeutics is a clinical-stage biotechnology company that is focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). However, the company faces significant competition in the biotechnology and pharmaceutical industries, and its product pipeline is still in the early stages with no products generating revenue. Additionally, the company will likely need to raise additional capital in the future, which may be difficult to obtain depending on market conditions. There is also a risk that the company's key intellectual property may fail to protect its products.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares